>
Sunday FULL SHOW: Newly Released & Verified Epstein Files Confirm Globalists Engaged...
Fans Bash Bad Bunny's 'Boring' Super Bowl Halftime Show, Slam Spanish Language Performan
Trump Admin Refuses To Comply With Immigration Court Order
U.S. Government Takes Control of $400M in Bitcoin, Assets Tied to Helix Mixer
SpaceX Authorized to Increase High Speed Internet Download Speeds 5X Through 2026
Space AI is the Key to the Technological Singularity
Velocitor X-1 eVTOL could be beating the traffic in just a year
Starlink smasher? China claims world's best high-powered microwave weapon
Wood scraps turn 'useless' desert sand into concrete
Let's Do a Detailed Review of Zorin -- Is This Good for Ex-Windows Users?
The World's First Sodium-Ion Battery EV Is A Winter Range Monster
China's CATL 5C Battery Breakthrough will Make Most Combustion Engine Vehicles OBSOLETE
Study Shows Vaporizing E-Waste Makes it Easy to Recover Precious Metals at 13-Times Lower Costs

A 13-year-old girl who was left completely bald from her alopecia has made an incredible transformation after taking an arthritis drug.
The unidentified teenager, from Brazil, had slowly been losing her hair for five years and standard medications failed to help. Doctors tried tofacitinib as a last-resort.
Tests of the drug, marketed as Xeljanz, have shown it can help alopecia patients regrow their hair – but it is not yet licensed as a conventional treatment.
After just four months, the girl regained a significant amount of her hair. She was left with thick, brown locks within two years of taking tofacitinib.
The results add to the evidence that the drug could offer hope for millions of patients around the world with alopecia, who have slim chances of making a full recovery.
Tofacitinib is routinely given to patient with rheumatoid arthritis, which is caused by inflammation. Dermatologists say the type of alopecia the girl had is caused by the same process.
Medical student Rachel Berbert Ferreira, at Centro Universitario Cesumar, was the senior author of the paper in Clinical Case Reports.